13D Filing: James E. Flynn and Nivalis Therapeutics Inc. (NVLS)

Page 5 of 16

Page 5 of 16 – SEC Filing

 SCHEDULE 13D

CUSIP No.  65481J109 Page 5 of 15 Pages
1

NAME OF REPORTING PERSONS

Deerfield Private Design Fund II, L.P.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☒

3

SEC USE ONLY

4

SOURCE OF FUNDS

WC

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

726,242

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

726,242

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

726,242

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

4.64%

14

TYPE OF REPORTING PERSON

PN

Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)

Page 5 of 16